Anti-Vascular Endothelial Growth Factor (VEGF)

    Anti-Vascular Endothelial Growth Factor Treatment for Retinal Conditions: A Systematic Review and Meta-analysis

    Bottom Line:

    • With a few exceptions, In comparison with other anti-vascular endothelial growth factor (anti-VEGF) drugs, intravitreal bevacizumab was a safe and effective alternative to ranibizumab and aflibercept in patients with various retinal conditions (e.g., choroidal neovascular age-related macular degeneration, diabetic macular edema, macular edema due to retinal vein occlusion and myopic choroidal neovascularization)
    • However, it is important to note that the choice of a specific anti-vascular endothelial growth factor (anti-VEGF) drug agent depends on the specific retinal condition, baseline visual acuity, and treatment regimen

    Impact:

    • Our results can be used by patients and physicians to tailor administration of these agents
    • Conducted for the Canadian Expert Drug Committee to make decisions on these agents
    • Results were used to build an economic model on these agents, which suggested saving at least $100 million for the Ontario government alone
    Funding:

    Canadian Institutes of Health Research (CIHR)/ Drug Safety and Effectiveness Network (DSEN) and Canadian Agency for Drugs and Technology in Health (CADTH)


    Anti–Vascular Endothelial Growth Factor Therapy for Age-related Macular Degeneration: Systematic Review and Network Meta-analysis

    Bottom Line:

    • In comparison with placebo drugs, anti-vascular endothelial growth factor (anti-VEGF) agents effectively improved vision gain and mean best-corrected visual acuity, and reduced vision loss
    • They are effective treatment options for patients with neovascular age-related macular degeneration
    • When assessing the comparative safety of anti-vascular endothelial growth factor (anti-VEGF) drugs with placebos, they were not associated with an increase in adverse events or increased mortality compared to placebo

    Impact:

    • Our results can be used by patients and physicians to tailor administration of these agents

    Protocol:

    Additional Resources:

    Funding:

    Canadian Institutes of Health Research (CIHR)/Drug Safety and Effectiveness Network (DSEN) and Canadian Agency for Drugs and Technology in Health (CADTH)

    Category :

    Date : 25 Aug 2017